• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.31% Nasdaq Up1.96%

    More On AMGN.MX

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials


    Amgen Inc. (AMGN.MX)

    -Mexico
    2,778.00 Down 4.65(0.17%) Jun 24
    ProfileGet Profile for:
    Amgen Inc.
    One Amgen Center Drive
    Thousand Oaks, CA 91320
    United States - Map
    Phone: 805-447-1000
    Fax: 805-447-1010
    Website: http://www.amgen.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:17,900

    Business Summary 

    Amgen Inc., a biotechnology company, engages in discovering, developing, manufacturing, and delivering human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its principal products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of high cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc.; UCB; Novartis AG; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Amgen Inc.

    Key Executives 
     PayExercised
    Mr. Robert A. Bradway , 53
    Chairman, Chief Exec. Officer, Chairman of Exec. Committee and Member of Equity Award Committee
    5.90M9.28M
    Mr. David W. Meline , 59
    Chief Financial Officer and Exec. VP
    3.59M0.00
    Mr. Jonathan P. Graham , 55
    Sr. VP, Gen. Counsel and Sec.
    4.18M0.00
    Dr. Sean E. Harper M.D., 53
    Exec. VP of R&D
    2.61M0.00
    Mr. Anthony C. Hooper , 61
    Exec. VP of Global Commercial Operations
    2.91M0.00
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in MXN.